Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Jupiter Neurosciences Inc (JUNS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jupiter Neurosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.42 +0.01    +0.71%
30/07 - Closed. Currency in USD
After Hours
1.52
+0.10
+7.04%
0:08:21 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 129,039
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.37 - 1.54
Jupiter Neurosciences 1.42 +0.01 +0.71%

Jupiter Neurosciences Inc Company Profile

 
Get an in-depth profile of Jupiter Neurosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

4

Equity Type

ORD

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson’s disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Contact Information

Address 1001 North US Highway 1 Suite 504
Jupiter, 33477
United States
Phone 561 406 6154
Fax -

Top Executives

Name Age Since Title
Raymond Scott Turner 65 2016 Member of Scientific Advisory Board
Li-Huei Tsai 63 2016 Member of Scientific Advisory Board
Peter Elliott 66 2016 Member of Scientific Advisory Board
Charbel Moussa 53 2020 Member of Scientific Advisory Board
Allison W. Brady 52 2021 Independent Director
W. Dalton Dietrich 73 2021 Member of Scientific Advisory Board
Rudolph Emile Tanzi 66 2019 Co-Chairman of Scientific Advisory Board
Nicholas H. Hemmerly 42 2021 Independent Director
Holger Weis 62 2021 Independent Director
Shaun P. Brothers 46 2016 Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research
Julie Kampf 62 2021 Independent Director
Claes Wahlestedt 66 2016 Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
Marshall Hayward 67 2016 Co-Founder, Chief Scientific Officer & Director
Christer Rosen 72 2016 Co-Founder, CEO & Chairman of the Board
Alison D. Silva 46 2018 President, Chief Business Officer & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JUNS Comments

Write your thoughts about Jupiter Neurosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email